Lee Logan, DO
Family Medicine · Dayton, TNNPI 1336188085
Payments from drug & device makers
Across 190 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$470
- AstraZeneca$283
- Lilly USA, LLC$266
- Boehringer Ingelheim$254
- Novartis$183
- Bayer$180
- plus $2K from 26 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$3,211100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $470 |
| AstraZeneca | 19 | $283 |
| Lilly USA, LLC | 18 | $266 |
| Boehringer Ingelheim | 15 | $254 |
| Novartis | 10 | $183 |
| Bayer | 10 | $180 |
| Sanofi-aventis U.S. LLC | 10 | $170 |
| Amgen | 8 | $165 |
| Esperion Therapeutics, Inc. | 9 | $140 |
| Pfizer | 8 | $139 |
| Merck | 9 | $128 |
| AbbVie(2 entities) | 7 | $120 |
| GSK | 4 | $77 |
| Avanir Pharmaceuticals, Inc. | 5 | $75 |
| Johnson & Johnson | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 4 | $64 |
| Medtronic | 3 | $63 |
| Silk Road Medical, Inc. | 1 | $47 |
| Indivior Inc. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Corcept Therapeutics | 1 | $22 |
| Abbott | 1 | $21 |
| Braeburn Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Grifols USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$101
How this compares
$3,222 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $102,625 |
| MounjaroTirzepatide | 82 | $102,091 |
| JardianceEmpagliflozin | 113 | $93,961 |
| OzempicSemaglutide | 67 | $85,544 |
| FarxigaDapagliflozin Propanediol | 97 | $76,128 |
| TrulicityDulaglutide | 49 | $62,546 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 45 | $50,914 |
| KerendiaFinerenone | 44 | $43,667 |
| Repatha SureclickEvolocumab | 77 | $41,437 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $41,123 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $40,735 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $36,182 |
| EntrestoSacubitril/Valsartan | 28 | $28,001 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $20,831 |
| XareltoRivaroxaban | 17 | $20,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat, Trijardy Xr, Stiolto Respimat | $254 | $178,372214 claims |
| Lilly USA, LLCMounjaro, Trulicity | $266 | $164,638131 claims |
| PfizerEliquis | $139 | $102,625133 claims |
| Novo NordiskOzempic | $470 | $85,54467 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $283 | $85,199110 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $77 | $54,81865 claims |
| BayerKerendia | $180 | $43,66744 claims |
| NovartisEntresto | $183 | $28,00128 claims |
| Johnson & JohnsonXarelto | $70 | $20,00617 claims |
| AbbVieLinzess, Synthroid | $120 | $16,27987 claims |
| Esperion Therapeutics, Inc.Nexletol | $140 | $7,52411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Dayton
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.